← Back to all trials
Not Yet Recruiting
NCT05677178
Response Prediction in EBV-HLH Using Metabonomics Analysis
Conditions: Hemophagocytic Lymphohistiocytoses, EBV, Metabonomics
Sex: All
Ages: 18 Years – 60 Years
Enrollment: 30
Sponsor: Beijing Friendship Hospital
Location: China
Summary
Hemophagocytic lymphohistiocytosis (HLH) is a rare, poorly recognized and underdiagnosed syndrome of excessive immune activation, which is rapidly fatal.
Epstein-Barr virus (EBV) is a common trigger of HLH, particularly in Asian individuals.
We aim to analyze metabolomics and cytokine profiles of patients before and after treatment to explore the metabolomic characteristics of EBV-HLH, and search for pathogenic mechanisms and therapeutic targets.
Eligibility Criteria
Inclusion Criteria:Patients who meet HLH-04 diagnostic criteriaEBV-DNA viral load in the peripheral blood > 500 copies/mLInformed consent obtained.Exclusion Criteria:refuse to participate.
Source: ClinicalTrials.gov (NCT05677178). StuddyBuddy aggregates publicly available trial information.
